Most Read Articles
Jairia Dela Cruz, 03 May 2018
Acute coronary syndrome (ACS) patients with diabetes mellitus, as well as high-risk nondiabetic patients, appear to obtain significant cardioprotection from the addition of ezetimibe to simvastatin, and this benefit is achieved without compromising safety, according to an exploratory analysis of data from IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial).
Pearl Toh, 28 Aug 2017
Taking long-chain omega-3 fatty acids (LC-OM3) supplements, mainly EPA* and DHA** omega-3s, was associated with a modest but significant reduction in cardiac death risk, according to a meta-analysis of randomized controlled trials (RCTs).
Dr. Lau Hui Ling, 01 Aug 2017
Oral contraceptive selection should be individualized for each patient to yield maximum benefit.
18 Apr 2016
Copper intrauterine device exhibited superior efficacy to injectable progestin contraception in women attending termination of pregnancy services in South Africa, according to a pragmatic, open-label, parallel arm, randomised controlled trial.

Pitavastatin superior to other statins for preventing diabetes in AMI patients

08 Oct 2018

Moderate-intensity pitavastatin appears to lower the incidence rate of new-onset diabetes mellitus (NODM) in acute myocardial infarction (AMI) patients, a recent study reports.

Researchers enrolled 2,001 AMI patients without diabetes mellitus, of whom 1,267 received atorvastatin (mean age 64.4±12.5 years; 76.6 percent male), 960 received rosuvastatin (mean age 63.2±12.4 years; 76.1 percent male) and 255 were given pitavastatin (mean age 63.4±12.0 years; 72.2 percent male). The cumulative NODM incidence was evaluated across the different groups.

Kaplan-Meier curves showed that the 3-year cumulative incidence rate of NODM was significantly lower in the pitavastatin group than in the atorvastatin and rosuvastatin groups (3.0 percent vs 8.4 percent and 10.4 percent; p=0.001).

Multivariate Cox regression analysis further provided proof for this association, showing that the type of statin taken was an important prognostic factor for NODM. Those who received atorvastatin (hazard ratio [HR], 2.6; 95 percent CI, 1.163–5.879; p=0.0201) or rosuvastatin (HR, 3.9; 1.756–8.689; p=0.0008) were significantly more likely to develop NODM than those who were given pitavastatin.

Notably, atorvastatin was superior to rosuvastatin in terms of NODM prognosis (HR, 0.669; 0.456–0.982; p=0.0401).

Other significant risk factors included triglyceride (HR, 1.004; 1.003–1.006; p<0.0001) and glucose (HR, 1.006; 1.003-1.008; p<0.0001) levels.

“The present study is the first study that evaluated the effect of statin type on NODM incidence in patients with AMI and compared diabetogenic effect among different same intensity statin therapies,” said researchers.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Jairia Dela Cruz, 03 May 2018
Acute coronary syndrome (ACS) patients with diabetes mellitus, as well as high-risk nondiabetic patients, appear to obtain significant cardioprotection from the addition of ezetimibe to simvastatin, and this benefit is achieved without compromising safety, according to an exploratory analysis of data from IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial).
Pearl Toh, 28 Aug 2017
Taking long-chain omega-3 fatty acids (LC-OM3) supplements, mainly EPA* and DHA** omega-3s, was associated with a modest but significant reduction in cardiac death risk, according to a meta-analysis of randomized controlled trials (RCTs).
Dr. Lau Hui Ling, 01 Aug 2017
Oral contraceptive selection should be individualized for each patient to yield maximum benefit.
18 Apr 2016
Copper intrauterine device exhibited superior efficacy to injectable progestin contraception in women attending termination of pregnancy services in South Africa, according to a pragmatic, open-label, parallel arm, randomised controlled trial.